Future Cardiology
Volume 17, 2021 - Issue 1
Open access
4,160
Views
0
CrossRef citations to date
0
Altmetric
Review
Impact of Expanded FDA Indication for Icosapent Ethyl On Enhanced Cardiovascular Residual Risk Reduction
William E Boden1 VA New England Healthcare SystemBostonMA& Boston University School of MedicineBostonMA02130USACorrespondence[email protected]
https://orcid.org/0000-0001-7145-8084
Seth Baum2 Boca Raton Regional Hospital Boca RatonFL33486USA
, Peter P Toth3 CGH Medical Center SterlingILJohns Hopkins University School of MedicineBaltimoreMD61081USA
, Sergio Fazio4 Oregon Health & Science UniversityPortlandOR97239USA
& Deepak L Bhatt5 Brigham & Women’s Hospital Heart & Vascular Center & Harvard Medical SchoolBostonMA02115USA
Pages 155-174
|
Received 29 Jun 2020, Accepted 19 Aug 2020, Published online: 22 Sep 2020
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.